Core Viewpoint - Dr. Wang Tao has resigned from his position as the employee representative supervisor of Youzhiyou Biotechnology-B (02496) for personal career development reasons, effective from December 31, 2025 [1] Group 1 - Dr. Shi Jian, the Director of the Translational Medicine Department, has been democratically elected as the employee representative supervisor of the second supervisory board, effective from December 31, 2025 [1] - Dr. Shi's term will commence on December 31, 2025, and will end when the second supervisory board concludes its term [1]

Core Viewpoint - The announcement details the resignation of Dr. Wang Tao from his position as employee representative supervisor at Youzhiyou Biotechnology-B (02496) due to personal career development reasons, effective from December 31, 2025 [1] Group 1 - Dr. Jian Shi, the Director of the Translational Medicine Department, will be democratically elected as the employee representative supervisor of the second supervisory board, effective from December 31, 2025 [1] - Dr. Shi's term will commence on December 31, 2025, and will conclude at the end of the second supervisory board's term [1]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 WUHAN YZY BIOPHARMA CO., LTD. 武 漢 友 芝 友 生 物 製 藥 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2496） 職工代表監事變更 石博士，1982年出生，現年43歲。石博士在生物制藥行業的治療性抗體、融合蛋 白及蛋白亞單位疫苗研發方面有逾15年研究經驗。石博士於2004年獲得武漢大學 生物科學學士學位，於2014年獲得武漢大學微生物學博士學位。石博士於2014年 至2018年在中國科學院武漢病毒研究所工作。石博士於2018年加入本公司，先後 擔任研發中心抗體工程技術部科學家、研發中心早期發展研究部副總監及總監、 研發中心轉化醫學部總監並兼任本公司工會主席。此外，石博士於2023年入選武 漢市「3551光穀人才計畫」的創新人才。 石博士已確認，除上文所披露者外，於本 ...

Core Viewpoint - The approval of the clinical trial for the biosimilar Y225 marks a significant advancement for the company in the treatment of Hemophilia A, potentially filling a gap in the domestic market for high-barrier bispecific monoclonal antibody biosimilars [1][2] Group 1: Product Development - The clinical trial for Y225, a biosimilar to the drug Shuyou Lile (Emicizumab), has been approved by the National Medical Products Administration (NMPA) of China [1] - Y225 is designed to treat Hemophilia A, a condition caused by a deficiency of coagulation factor VIII, which leads to bleeding disorders [1] - The original drug Shuyou Lile is the only bispecific antibody available for preventive treatment in patients with or without factor VIII inhibitors, but its high cost limits accessibility for patients [1] Group 2: Competitive Advantage - The company has innovatively overcome the formulation patent of the original drug, allowing Y225 to potentially launch seven years earlier than expected, making it the first biosimilar of Shuyou Lile in the domestic market [1] - The existing patents for the original drug extend its protection until 2038, creating a high barrier to entry for competitors [1] Group 3: Strategic Collaborations - A strategic cooperation agreement was signed with Hubei Jiangxia Laboratory to leverage their research capabilities alongside the company's experience in antibody drug development [2] - The collaboration will focus on innovative antibody molecular design, efficient production process development, and clinical research, with Y225 as the first project [2] - This partnership aims to enhance the overall research and development efficiency and long-term industrialization potential of the company's pipeline [2]

Company News - Bank of China (03988.HK) has completed the issuance of 50 billion yuan in subordinated capital bonds, with the funds intended to supplement the bank's Tier 2 capital, subject to applicable laws and regulatory approvals [2] - Huadian International Power (01071.HK) has fully commissioned two 660,000 kW ultra-supercritical units at the Huadian Longkou Phase IV project, which integrates advanced technologies and achieves energy consumption levels comparable to the best in the domestic market, enhancing grid stability and local heating and industrial steam supply [2] - Weisheng Holdings (03393.HK) has entered into a capital increase agreement with Boyu Capital, with Boyu investing a total of 380 million yuan to subscribe for additional shares in its subsidiary [3] - Green Leaf Pharmaceutical (02186.HK) has granted Enhua exclusive commercialization rights for three long-acting injectable antipsychotic products in mainland China [4] - Heng Rui Medicine (01276.HK) has had its injectable SHR-A1904 included in the list of breakthrough therapy products by the drug review center [5] - Youzhiyou Biotechnology-B (02496.HK) has received IND approval from NMPA for Y225 (Aimeisai monoclonal antibody injection) [6] - MicroPort Robotics-B (02252.HK) has achieved a global commercialization milestone with over 100 installations of its Tumi laparoscopic surgical robot [7] - Gao Shan Enterprises (00616.HK) has signed a memorandum of understanding to establish a joint venture to participate in or invest in stablecoins and blockchain-related industries [8] - Energy International Investment (00353.HK) plans to issue a total of 1.035 billion subscription shares at a discount of approximately 18.33%, aiming to raise about 254 million HKD [9] Buyback Activities - Tencent Holdings (00700.HK) has repurchased approximately 636 million HKD worth of 1.056 million shares at prices ranging from 598 to 604 HKD [10] - Xiaomi Group-W (01810.HK) has spent 149 million HKD to repurchase 3.8 million shares at prices between 39.08 and 39.26 HKD [11] - China COSCO Shipping Holdings (01919.HK) has repurchased shares worth approximately 27.225 million HKD, acquiring 1.96 million shares at prices from 13.82 to 13.95 HKD [12] - Kuaishou-W (01024.HK) has repurchased shares for about 29.9896 million HKD, buying 464,000 shares at prices between 64.05 and 64.9 HKD [13]

Core Viewpoint - The approval of the clinical trial for the biosimilar Y225 marks a significant advancement for the company in the treatment of Hemophilia A, potentially filling a gap in the domestic market for high-barrier bispecific monoclonal antibody biosimilars [1][2] Group 1: Product Development - The clinical trial for Y225, a biosimilar to the drug Shuyou Lile® (Emicizumab injection), has been approved by the National Medical Products Administration (NMPA) of China, with the trial set to begin on December 23, 2025 [1] - Y225 is designed to treat Hemophilia A, a condition caused by a deficiency in coagulation factor VIII, which leads to bleeding disorders [1] - The original drug Shuyou Lile® is the only bispecific antibody approved for preventive treatment in patients with or without factor VIII inhibitors, but its high cost limits patient access [1] Group 2: Competitive Advantage - The company has innovatively overcome the formulation patent of the original drug, allowing Y225 to potentially launch seven years earlier than expected, making it the first biosimilar of Shuyou Lile® to enter the domestic market [1] - The existing patents for Shuyou Lile® extend its protection until 2038, creating a significant barrier to entry for competitors [1] Group 3: Strategic Partnerships - A strategic cooperation agreement was signed with Hubei Jiangxia Laboratory on June 17, 2025, to leverage the laboratory's research capabilities alongside the company's experience in antibody drug development [2] - The collaboration will focus on innovative antibody molecule design, efficient production process development, and clinical research, with Y225 as the first project [2] - This partnership aims to enhance the overall research and development efficiency and long-term industrialization potential of the company's pipeline [2]

Core Viewpoint - Youzhiyou Biotech-B (02496.HK) has received approval from the National Medical Products Administration (NMPA) of China for the clinical trial application of its biosimilar Y225, aimed at treating Hemophilia A [1][2] Group 1: Product and Market Potential - Y225 is a biosimilar of the dual-specific antibody Shuyou Lile® (Emicizumab injection), which targets FIX and FX for the treatment of Hemophilia A [1] - The original drug Shuyou Lile® is the only dual antibody medication available for preventive treatment in patients with or without factor VIII inhibitors, offering advantages such as once every four weeks dosing and subcutaneous injection [1] - The high cost of Shuyou Lile® limits patient access, and over 20% of Hemophilia A patients develop inhibitors that affect treatment efficacy [1] - The original drug has a patent protection period extended to 2038, but the company has innovatively overcome the formulation patent, allowing Y225 to potentially launch seven years earlier, filling a gap in the domestic market for high-barrier biosimilars [1] Group 2: Clinical Trial Details - The approved clinical trial is a randomized, double-blind, single-dose, parallel-comparison study assessing the bioequivalence of Shuyou Lile® and Y225 in healthy male subjects [2] - The trial is led by Dr. Huang Chaolin from Wuhan Jinyintan Hospital as the principal investigator [2]

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 自願公告 WUHAN YZY BIOPHARMA CO., LTD. Y225「艾美賽珠單抗注射液」取得NMPA的IND批准 本 公 告 由 武 漢 友 芝 友 生 物 製 藥 股 份 有 限 公 司（「本 公 司」， 連 同 其 附 屬 公 司 ， 統 稱 「本 集團」）自 願作 出 ，以 告知 本 公司 股東 及 潛在 投 資者 有關 本 公司 的 最新 業務 發 展情況。 本公司欣然宣佈，於2025年12月23日，其生物類似藥Y225的臨床試驗（「IND」）申 請已獲中華人民共和國國家藥品監督管理局（「NMPA」）批准。 武 漢 友 芝 友 生 物 製 藥 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2496） 香港聯合交易所有限公司證券上市規則第18A .05條規定的示警聲明：本公司無法 保證能 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 武漢友芝友生物製藥股份有限公司 (於中華人民共和國註冊成立的股份有限公司) 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02496 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 111,468,814 | RMB | | 1 RMB | | 111,468,814 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 111,468,814 | RMB | | 1 RMB | | 111,468,814 | | 2. ...

Core Viewpoint - The company, Youzhiyou Biotechnology-B (02496), has announced the publication of clinical trial results for its dual-target bispecific antibody drug M701, which targets Ep CAM and CD3, in treating malignant ascites caused by advanced epithelial tumors. This recognition by an international medical journal signifies the clinical value of the innovative therapy [1]. Group 1: Clinical Trial Results - The Phase II study aimed to evaluate the efficacy and safety of M701 administered via intraperitoneal infusion in patients with moderate to severe malignant ascites due to advanced epithelial tumors [1]. - A total of 84 patients were enrolled in the study, with 43 patients assigned to the M701 group, who received abdominal puncture and M701 infusion [1]. - The median puncture-free survival time for the M701 group was 75 days, compared to 25 days for the control group, showing a significant difference (p=0.0065) [1]. Group 2: Efficacy Across Cancer Types - Subgroup analysis indicated that various cancer types, including gastric cancer, colorectal cancer, and ovarian cancer, benefited from M701 infusion [1]. - Patients with a baseline relative lymphocyte count of ≥13% experienced better efficacy from the treatment [1]. - The overall survival time for patients in the M701 group was extended compared to the control group, with 6-month survival rates of 33.3% for the M701 group versus 12.1% for the control group [1]. Group 3: Safety Profile - No serious adverse events were observed in the M701 group during the study [1].